{"prompt": "['HORIZON', 'Official Title:', 'Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001)', 'Treatment in Subjects with Thyroid Eye Disease (OPTIC-X)', 'Document:', 'Protocol', 'NCT#:', 'NCT03461211', 'Document Date:', '31 January 2019', '1 Horizon Way, Deerfield, IL 60015']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'H', 'HORIZON', 'P H A R M A', 'CLINICAL STUDY PROTOCOL', 'FOR TEPROTUMUMAB (HZN-001)', 'IND: 112952', 'Protocol Number: HZNP-TEP-302', 'EudraCT Number: 2017-002713-58', 'Multicenter, Safety and Efficacy, Open-Label Extension Study', 'Evaluating Teprotumumab (HZN-001) Treatment', 'in Subjects with Thyroid Eye Disease', 'Short Title: @PTIC-X\"', \"Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in\", 'an Open-Label Clinical Extension Study', 'Date: 31 January 2019', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Sponsor:', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'This protocol is the confidential information of Horizon Pharma USA, Inc. and is intended solely for the guidance of the clinical', 'investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the', 'prior written consent of Horizon Pharma USA, Inc.', 'CONFIDENTIAL', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 1 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'PROTOCOL', '1', 'TITLE PAGE', 'Study Title: Multicenter, Safety and Efficacy, Open-Label Extension Study', 'Evaluating Teprotumumab (HZN-001) Treatment in Subjects with', 'Thyroid Eye Disease (OPTIC-X)', 'Protocol Number: HZNP-TEP-302', 'Version: 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Investigational Product: Teprotumumab (HZN-001)', 'Indication: Thyroid Eye Disease (TED)', \"(also called Graves' Ophthalmopathy or Orbitopathy [GO] and\", 'Thyroid-Associated Ophthalmopathy [TAO]).', 'Sponsor: Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Development Phase: 3', \"Sponsor's Responsible\", 'Medical Officer:', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Sponsor Signatory:', 'Horizon Pharma USA, Inc.', 'Approval Date: 31 January 2019', 'CONTACT IN THE EVENT OF AN EMERGENCY', 'Any death, life threatening event, or other Serious Adverse Event experienced by a subject', 'during the course of the study, whether or not judged drug-related, must be reported within', '24 hours of knowledge of the event by entering the information into the electronic case report', 'form (eCRF). If unable to access the electronic case report form, the event must be reported by', 'submitting the completed Serious Adverse Event Form via email or fax to the contact numbers', 'provided below.', 'Fax:', 'Email:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 2 of 118']\n\n###\n\n", "completion": "END"}